Sentences with phrase «relations company based»

Silvio Marcacci Silvio is Principal at Marcacci Communications, a full - service clean energy and climate policy public relations company based in Oakland, CA.

Ed Zitron is the CEO of EZPR, a Media Relations company based in San Francisco, Boston and Portland.

Silvio Marcacci Silvio is Principal at Marcacci Communications, a full - service clean energy and climate policy public relations company based in Oakland, CA.

Not exact matches

«In 2000, the tech companies coming out of L.A. were a joke,» says Francisco Dao, president of The Killer Pitch, a Public Relations firm based in Tarzana, California.

A Bibra Lake - based transport company has been fined $ 30,000 in relation to a workplace incident where a mechanic had his legs crushed under the wheels of a truck trailer driven by one of the directors of the company.

Acting on it is another thing altogether,» says David Ambler, a partner in the Phelon Group, a consultancy based in Palo Alto, California, which focuses on helping companies better relations with customers.

Niko Resources, a Calgary - based oil and gas company for which Sharif was the senior in - country executive, was being accused of bribery, thereby jeopardizing diplomatic relations.

Mark Braff, founder of Braff Communications, a Fair Lawn, New Jersey - based consumer and B2B public relations company:

Jason Mandell, partner at LaunchSquad, a San Francisco - based Inc. 5000 marketing and public relations company:

Barry Racey, AK Steel's public relations director, offered some explanation for Wainscott's pay bump: «2014 compensation decisions were made early in the... year, and were largely based on 2013 company performance.

There are lots of dumb things you could do as a startup entrepreneur — like base your company out of Bakersfield, allow yourself to be acquired by Groupon in an all - stock transition, or pitch your growing U.S. - based startup to the Samwer brothers — but nothing could be more dumb than throwing your hard - earned venture capital money at a public relations firm.

Based on their discussions with the company's investor relations team, analysts think the claims are associated with «a potential misrepresentation of the magnitude of the benefit of skincare and makeup products,» the note said.

British Journal of Industrial Relations, 54 (1) 2016, 55 - 82, showing that such companies had higher return on equity than low equity and profit sharing companies, based on a sample representing 10 % of sales and employment and 20 % of total market value of the entire NYSE and NASDAQ comparing companies with broad - based shares to companies without broad - based shares.

One of the most productive link building strategies is where companies leverage a SEO consultant's expertise for the mechanics of content based link building in addition to gaining an understanding of how to leverage what corporate communications, PR, HR, Marketing, Sales and even Investor Relations are already doing that could result in relevant inbound links.

The second floor of a two - story building with a failed cooling system would almost always be hotter than the lower floor, especially in Florida, said Todd Washam, director of industry and external relations at the Air Conditioning Contractors of America, a group based in Arlington, Va., that represents 4,000 companies nationwide.

These companies have demonstrated strong financial positions through passing the rigorous requirements of the Defensive Investor, and show potential for capital growth based on their current price in relation to intrinsic value.

As with all startups, he wears a number of hats, but is generally tasked with setting the overall strategy for the company and on a daily basis oversees Sales, Marketing, Finance, and Investor Relations.

The exhibition centre will benefit from UCIMA's international relations network and the assistance offered by member companies for the creation of an event that meets the expectations of its international customer - base.

Archer Daniels Midland Company (ADM) has been granted exclusivity in relation to the proposed purchase of Chamtor, a French producer of wheat - based sweeteners and starches.

Kawasaki Kisen Kaisha (K - line), a Japan - based shipping company, today entered a guilty plea in relation to criminal cartel conduct.

Public records indicate that between January and June of this year, Genting spent $ 340,000 on lobbying, with $ 100,000 going to the Albany - based government - relations firm Meara Avella Dickinson; $ 25,000 going to Patricia Lynch and Associates, headed by the Assembly speaker's former top aide; $ 195,000 going to Cordo and Company; and $ 20,000 going to Empire Strategic Planning.

Any water, including rain and snow, that comes in contact with mining activities is sent to a $ 10 - million water treatment plant that will use a cleansing technology called reverse osmosis, said Daniel Blondeau, communications and media relations advisor at Rio Tinto, the London - based mining company that owns Kennecott.

The Web site is sponsored by the Center for Consumer Freedom, created by a public relations firm that represents a coalition of animal - based consumer products companies, restaurants, and «concerned individuals».

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & AcquisiBased on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

To add more subjects, more grade levels,» says Edward G. Roeber, the vice president for external relations for Advanced Systems in Measurement and Evaluation Inc., a testing company based in Dover, N.H.

The purpose of this game - based onboarding course was to train new hires on the company, its services, employee relations and performance management, in an engaging way.

Tokyo - based Takata Corporation, one of the world's largest suppliers of automotive safety - related equipment, agreed to plead guilty to wire fraud and pay a total of $ 1 billion in criminal penalties stemming from the company's fraudulent conduct in relation to sales of defective airbag inflators.

Based on first quarter results, and a schedule of current rig utilization and contracted dayrates provided by Investor Relations, we expect the company to earn $ 35 - 50m in cash from operations during 2009.

The site's design and concept was based on research on current web - based services and company president» Lea - Ann Germinder's 20 years in public relations.

«Pets are a great subject for the social media because owners are passionate about them,» explains Lyn Mettler, founder and co-owner of the Charleston, S.C. - based Step Ahead Inc., a social media, online marketing and public relations company.

Creations, an L.A. - based public relations firm, as one of fifteen companies whose products will be gifted to the Obamas in a First Puppy Gift box.

Hobson, whose company is based in SantaFe, will serve as the main point of contact for all media relations in North America and will focus on consumer media outreach regarding the ATTA and the adventure industry on the whole.

* Here is that hearing that took place, it's lengthy but first the claims are made, the panels give their respective views based on their background and relation to the industry and where they see it going followed by Sega (represented by Bill White) and Nintendo's Howard Lincoln answering the challenges and facing off against each other, challenging each companies approach to the industry, worth a watch, history in the making ~ https://m.youtube.com/watch?v=nD-Afpg4P2U

The claim is confusing but addresses the duplicity of companies like Exxon to manoeuvre around the public relations problem instead of dealing with it purely on the basis of the science.

As part of this effort, the «Global Strategy Group, a D.C. - based crisis management public relations firm working on behalf of Edison Electric Institute, APS's trade association, tried to secretly shop stories to local media outlets aimed at smearing a local solar panel company's employee, who lashed out at APS in an email to his customers» reported the Arizona Capitol Times.

Based in the UAE for 8 years, he is experienced in advising companies and individuals on the UAE local courts procedures for a variety of disputes in relation to banking facilities, finance claims and labour disputes.

a) The substantial law b) The assessment of damages c) The fact that most insurance companies are UK based and insurers administrative systems will tend to treat Scottish and English systems, particularly in relation to assessment of damages, in a similar manner.

Global law firm Norton Rose Fulbright has advised FTSE 250 - listed company, Tullow Oil plc, in relation to the refinancing of its US$ 2.5 billion reserves based lending facilities and consequential amendments to its $ 600 million senior secured revolving credit facility.

«LS»: instructed to advise on an urgent basis in relation to financing dispute which had arisen between shipyard and Owner company.

Your lawyer can guide you in relation to the general structure of your company, including the drafting of a Shareholders» Agreement to ensure that you know from the outset how your company will operate on a day to day basis, and the production of bespoke Articles of Association.

Advising a large international ship owning company in relation to allegations that it had obtained preferential charter rates from a company based in the CIS by paying bribes.

Global law firm Norton Rose Fulbright has advised FTSE 250 - listed company, Tullow Oil plc, in relation to the refinancing of its US$ 2.5 billion reserves based...

Emma notably acted for the Directors of London based oil and gas company, Soma, in relation to the SFOs investigation into allegations of bribery and corruption as well as a...

For companies operating, or involved, in the global betting and gaming sector, we provide a full range of legal services, be it in relation to land - based or online operations.

The Company appealed against the decision to award Mr King payment for category 3 holiday pay above on the basis that he had never attempted to exercise his rights in relation to this leave and the right was therefore lost.

Representing a shareholder of a CIS based oil company in respect of an application to set aside a worldwide freezing order in relation to a claim alleging conspiracy valued at over $ 350m.

Standing next to his futuristic concept helicopter, the FCX - 001, in the lobby of his Fort Worth - based company, Snyder said Uber's reputation shouldn't be a concern in relation to this project.

Similar to how Twitter is now trying to make things right with its user base - who have too often been the victims of harassment, abuse, hate, and threats of violence — the company has been trying to reset relations with its developer community, too.

Remember that the employer has to base a major part of his decision on your objectives in relation to the objectives of the company.

Launch Recruitment is working with a highly reputable and market leading company based in Doncaster to recruit a Sales Coordinator who will assist and support the Area Sales Manager in order to increase sales through building and creating effective customer relationships You will also be required to co-ordinate between sales and operations to ensure that customers» expectations are met in relation to order requirements and delivery.